- Home
- RVPH vs AVTX Comparison
RVPH vs AVTX Comparison
Compare RVPH & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVPH
- AVTX
- Stock Information
- Founded
- RVPH 2006
- AVTX 2011
- Country
- RVPH United States
- AVTX United States
- Employees
- RVPH N/A
- AVTX N/A
- Industry
- RVPH Biotechnology: Pharmaceutical Preparations
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- RVPH Health Care
- AVTX Health Care
- Exchange
- RVPH Nasdaq
- AVTX Nasdaq
- Market Cap
- RVPH 32.8M
- AVTX 57.4M
- IPO Year
- RVPH N/A
- AVTX 2015
- Fundamental
- Price
- RVPH $0.39
- AVTX $4.94
- Analyst Decision
- RVPH Strong Buy
- AVTX Strong Buy
- Analyst Count
- RVPH 5
- AVTX 7
- Target Price
- RVPH $9.00
- AVTX $31.00
- AVG Volume (30 Days)
- RVPH 2.5M
- AVTX 99.4K
- Earning Date
- RVPH 08-13-2025
- AVTX 08-11-2025
- Dividend Yield
- RVPH N/A
- AVTX N/A
- EPS Growth
- RVPH N/A
- AVTX N/A
- EPS
- RVPH N/A
- AVTX N/A
- Revenue
- RVPH N/A
- AVTX $441,000.00
- Revenue This Year
- RVPH N/A
- AVTX N/A
- Revenue Next Year
- RVPH N/A
- AVTX N/A
- P/E Ratio
- RVPH N/A
- AVTX N/A
- Revenue Growth
- RVPH N/A
- AVTX N/A
- 52 Week Low
- RVPH $0.30
- AVTX $3.39
- 52 Week High
- RVPH $4.28
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- RVPH 31.05
- AVTX 57.06
- Support Level
- RVPH $0.30
- AVTX $4.50
- Resistance Level
- RVPH $0.83
- AVTX $5.05
- Average True Range (ATR)
- RVPH 0.07
- AVTX 0.32
- MACD
- RVPH -0.04
- AVTX 0.03
- Stochastic Oscillator
- RVPH 16.04
- AVTX 81.36
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).